JAMA Neurology Current Issuehttp://archneur.jamanetwork.com/
en-usWed, 01 Jul 2015 00:00:00 GMTMon, 13 Jul 2015 11:43:47 GMTSilverchaireditor@archneur.jamanetwork.comwebmaster@archneur.jamanetwork.comJuly 2015 Issue Highlightshttp://archneur.jamanetwork.com/article.aspx?articleID=2383116
Wed, 01 Jul 2015 00:00:00 GMT72773573510.1001/jamaneurol.2014.2856http://archneur.jamanetwork.com/article.aspx?articleID=2383116Affordable Care Act and Chronic Neurological Illnesseshttp://archneur.jamanetwork.com/article.aspx?articleID=2277722
Wed, 01 Jul 2015 00:00:00 GMTEsper GJ, Hartung D, Avitzur O. <span class="paragraphSection">This Viewpoint discusses the costs associated with care for chronic neurological illnesses for patients with health insurance exchange plans, established through the Patient Protection and Affordable Care Act.</span>72773974010.1001/jamaneurol.2015.0273http://archneur.jamanetwork.com/article.aspx?articleID=2277722Advances in Muscular Dystrophieshttp://archneur.jamanetwork.com/article.aspx?articleID=2289169
Wed, 01 Jul 2015 00:00:00 GMTKang PB, Griggs RC. <span class="paragraphSection">Muscular dystrophy (MD) was originally defined as a single disease in the 19th century. In the 20th century, MD was delineated into the following 6 subcategories: Duchenne MD (DMD)/Becker MD, limb-girdle MD, distal myopathies, congenital MD, facioscapulohumeral MD, and myotonic dystrophy. Since the cloning of dystrophin in 1986, a flood of genetic discoveries has made it apparent that <span style="font-style:italic;">muscular dystrophy</span> actually refers to a superfamily of more than 50 distinct diseases definable by specific genetic mutations. Thus, this term is rapidly becoming an anachronism that is likely to be replaced by specific molecular diagnoses. Adding to the complexity, many causative genes are associated with multiple phenotypes, such as the link between dysferlin and both Miyoshi myopathy and limb-girdle MD 2B. However, specific genotype-phenotype associations still provide guidance regarding which genes are likely to harbor pathogenic mutations. Whole-exome sequencing and whole-genome sequencing are becoming widely available diagnostic tools. Moreover, new diseases continue to be identified by whole-exome sequencing and whole-genome sequencing, some of which are exceedingly rare but have important mechanistic and therapeutic connections to other MDs. Diagnosis is further complicated by the clinical overlap between MDs and other inherited myopathies, illustrated by our work on <span style="font-style:italic;">MEGF10</span> myopathy. Whole-exome sequencing, whole-genome sequencing, and sophisticated bioinformatic strategies also promise to identify genes, such as <span style="font-style:italic;">LTBP4</span> in DMD, that modify the course or treatment responses of these mendelian disorders.</span>72774174210.1001/jamaneurol.2014.4621http://archneur.jamanetwork.com/article.aspx?articleID=2289169Clinical Trials of Therapies for Amyotrophic Lateral Sclerosishttp://archneur.jamanetwork.com/article.aspx?articleID=2279880
Wed, 01 Jul 2015 00:00:00 GMTGoutman SA, Feldman EL. <span class="paragraphSection">This Viewpoint discusses amyotrophic lateral sclerosis as a syndrome rather than a single disease that requires varied diagnostic and therapeutic approaches.</span>72774374410.1001/jamaneurol.2014.4275http://archneur.jamanetwork.com/article.aspx?articleID=2279880 JAMA Neurology Clinical Challengehttp://archneur.jamanetwork.com/article.aspx?articleID=2293513
Wed, 01 Jul 2015 00:00:00 GMTHonig LS, Rosenberg RN. <span class="paragraphSection"><span style="font-style:italic;">JAMA Neurology</span> has officially started its new journal feature, the Clinical Challenge. This section, which is under the editorship of Lawrence S. Honig, MD, PhD, had its first article published online March 30, 2015. This article type will be initially published 4 times per year, with a planned expansion to 6 times per year.</span>72774574510.1001/jamaneurol.2015.0802http://archneur.jamanetwork.com/article.aspx?articleID=2293513In-Hospital Strokehttp://archneur.jamanetwork.com/article.aspx?articleID=2277719
Wed, 01 Jul 2015 00:00:00 GMTDulli DA. <span class="paragraphSection">There have been tremendous strides in standardization of the care for acute ischemic stroke since widespread use of thrombolytic therapy began almost 20 years ago. Efficacy is still limited by delayed presentation to the emergency department following stroke symptom onset, although this has also improved in that period with education of emergency medical services and the community at large. The real improvement lies in development of streamlined and standardized protocols for “code stroke,” so that thrombolysis rates of 20% are becoming typical and door-to-needle times are just as typically under 1 hour. These encouraging developments are enhanced yet further by the evolution of stroke units, multidisciplinary stroke teams, and telemedicine to maximize the benefit of whatever window of opportunity presents to the emergency department door. Of course, these developments have primarily been aimed through these years at that door.</span>72774674610.1001/jamaneurol.2015.0370http://archneur.jamanetwork.com/article.aspx?articleID=2277719Targeting the Interleukin 6 Receptor to Treat Neuromyelitis Opticahttp://archneur.jamanetwork.com/article.aspx?articleID=2289165
Wed, 01 Jul 2015 00:00:00 GMTIrani SR, Vincent A. <span class="paragraphSection">The number of different antibody-associated disorders of the central nervous system and the clinical phenotypes encountered are increasing steadily. Because these patients have potentially reversible diseases, it is incumbent on the neurologist to treat them promptly and effectively. However, although some diseases respond fairly well and quickly to conventional immunotherapies, some can be very challenging.</span>72774774810.1001/jamaneurol.2015.0579http://archneur.jamanetwork.com/article.aspx?articleID=2289165Care and Outcomes of Patients With In-Hospital Strokehttp://archneur.jamanetwork.com/article.aspx?articleID=2277721
Wed, 01 Jul 2015 00:00:00 GMTSaltman AP, Silver FL, Fang J, et al. <span class="paragraphSection">This prospective cohort study examines stroke care delivery and outcomes for patients with in-hospital vs community-onset stroke.</span>72774975510.1001/jamaneurol.2015.0284http://archneur.jamanetwork.com/article.aspx?articleID=2277721IL-6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorderhttp://archneur.jamanetwork.com/article.aspx?articleID=2289167
Wed, 01 Jul 2015 00:00:00 GMTRingelstein M, Ayzenberg I, Harmel J, et al. <span class="paragraphSection">This retrospective observational study evaluates the long-term safety and efficacy of tocilizumab, a humanized antibody targeting the interleukin 6 receptor, in 8 female patients with neuromyelitis optica (NMO) and NMO spectrum disorder. See the Editorial by Vincent.</span>72775676310.1001/jamaneurol.2015.0533http://archneur.jamanetwork.com/article.aspx?articleID=2289167Standard vs Modified Antiplatelet Preparation in Patients With Coil Embolizationhttp://archneur.jamanetwork.com/article.aspx?articleID=2293516
Wed, 01 Jul 2015 00:00:00 GMTHwang G, Huh W, Lee J, et al. <span class="paragraphSection">This randomized clinical trial evaluates the effect of standard vs modified antiplatelet preparation in patients with high on-treatment platelet reactivity undergoing coil embolization in unruptured aneurysms.</span>72776477210.1001/jamaneurol.2015.0654http://archneur.jamanetwork.com/article.aspx?articleID=2293516Memory and Concussion History in Retired National Football League Athleteshttp://archneur.jamanetwork.com/article.aspx?articleID=2289166
Wed, 01 Jul 2015 00:00:00 GMTStrain JF, Womack KB, Didehbani N, et al. <span class="paragraphSection">This retrospective cohort study reports that prior concussion resulting in loss of consciousness is a risk factor for increased hippocampal atrophy and the development of MCI. In individuals with MCI, hippocampal volume loss appears more prevalent among those with a history of concussion.</span>72777378010.1001/jamaneurol.2015.0206http://archneur.jamanetwork.com/article.aspx?articleID=2289166Genetic Variants Associated With Risk of Ischemic Strokehttp://archneur.jamanetwork.com/article.aspx?articleID=2279879
Wed, 01 Jul 2015 00:00:00 GMTAuer PL, Nalls M, Meschia JF, et al. <span class="paragraphSection">This genome-wide association study identifies 2 novel genes, <span style="font-style:italic;">PDE4DIP</span> and <span style="font-style:italic;">ACOT4</span>, that are associated with an increased risk for ischemic stroke.</span>72778178810.1001/jamaneurol.2015.0582http://archneur.jamanetwork.com/article.aspx?articleID=2279879Alzheimer Disease With and Without Lewy Bodieshttp://archneur.jamanetwork.com/article.aspx?articleID=2289168
Wed, 01 Jul 2015 00:00:00 GMTChung E, Babulal GM, Monsell SE, et al. <span class="paragraphSection">This retrospective study suggests that Lewy body–related phenotypes within Alzheimer disease may be useful in distinguishing the presence of comorbid Lewy body pathology.</span>72778979610.1001/jamaneurol.2015.0606http://archneur.jamanetwork.com/article.aspx?articleID=2289168Novel Mutation in ELOVL4 Leading to Spinocerebellar Ataxiahttp://archneur.jamanetwork.com/article.aspx?articleID=2293515
Wed, 01 Jul 2015 00:00:00 GMTOzaki K, Doi H, Mitsui J, et al. <span class="paragraphSection">This genetic study identifies the causative gene of spinocerebellar ataxia in 2 Japanese families with distinct neurological symptoms and radiological presentations.</span>72779780510.1001/jamaneurol.2015.0610http://archneur.jamanetwork.com/article.aspx?articleID=2293515Risk of Neuropathy in Patient With Biopsy-Verified Celiac Diseasehttp://archneur.jamanetwork.com/article.aspx?articleID=2279878
Wed, 01 Jul 2015 00:00:00 GMTThawani SP, Brannagan TH, III, Lebwohl B, et al. <span class="paragraphSection">This population-based study showed that celiac disease was associated with a 2.5-fold increased risk of later neuropathy, including chronic inflammatory demyelinating neuropathy, autonomic neuropathy, and mononeuritis multiplex.</span>72780681110.1001/jamaneurol.2015.0475http://archneur.jamanetwork.com/article.aspx?articleID=2279878The Future of Research in Myastheniahttp://archneur.jamanetwork.com/article.aspx?articleID=2293518
Wed, 01 Jul 2015 00:00:00 GMTRichman DP. <span class="paragraphSection">This Special Communication reports on the latest research in myasthenia, which results from dysfunction of the neuromuscular synapse (ie, the neuromuscular junction), causing clinical “fatigue” that is defined as muscle weakness that worsens with muscle use and improves with rest.</span>72781281410.1001/jamaneurol.2014.4740http://archneur.jamanetwork.com/article.aspx?articleID=2293518Use of Advanced MRI Techniques in NMO Spectrum Disorderhttp://archneur.jamanetwork.com/article.aspx?articleID=2293517
Wed, 01 Jul 2015 00:00:00 GMTKremer S, Renard F, Achard S, et al. <span class="paragraphSection">This review summarizes the literature on advanced quantitative imaging measures reported for patients with neuromyelitis optica spectrum disorder, including proton magnetic resonance spectroscopy, diffusion tensor imaging, magnetization transfer imaging, quantitative magnetic resonance volumetry, and ultrahigh-field strength magnetic resonance imaging.</span>72781582210.1001/jamaneurol.2015.0248http://archneur.jamanetwork.com/article.aspx?articleID=2293517Neuroelectronics and Bioopticshttp://archneur.jamanetwork.com/article.aspx?articleID=2279876
Wed, 01 Jul 2015 00:00:00 GMTKrook-Magnuson E, Gelinas JN, Soltesz I, et al. <span class="paragraphSection">This article discusses how advances in experimental closed-loop systems hold promise for improved clinical benefit in patients with neurological disorders.</span>72782382910.1001/jamaneurol.2015.0608http://archneur.jamanetwork.com/article.aspx?articleID=2279876Eight-and-a-Half Syndromehttp://archneur.jamanetwork.com/article.aspx?articleID=2279877
Wed, 01 Jul 2015 00:00:00 GMTBocos-Portillo J, Ojeda J, Gomez-Beldarrain M, et al. <span class="paragraphSection">An 81-year-old patient was seen with sudden onset of ophthalmoplegia and unsteadiness. His medical record included hypertension, type 2 diabetes mellitus, and hypercholesterolemia. The neurological examination disclosed left internuclear ophthalmoplegia and horizontal left-sided gaze palsy, accompanied by left-sided peripheral facial palsy (VideoVideo). The physical examination findings were otherwise normal.</span>72783083010.1001/jamaneurol.2015.0255http://archneur.jamanetwork.com/article.aspx?articleID=2279877Papilledema From Intraventricular Neurocysticercosishttp://archneur.jamanetwork.com/article.aspx?articleID=2293514
Wed, 01 Jul 2015 00:00:00 GMTHuang LC, Sridhar J. <span class="paragraphSection">This case report describes a woman with neurocysticercosis manifesting as blurry vision, tinnitus, and multiple posterior fossa cysts requiring surgical drainage.</span>72783183110.1001/jamaneurol.2015.0470http://archneur.jamanetwork.com/article.aspx?articleID=2293514Recovery From Locked-in Syndromehttp://archneur.jamanetwork.com/article.aspx?articleID=2383121
Wed, 01 Jul 2015 00:00:00 GMTHocker S, Wijdicks EM. <span class="paragraphSection">This case report describes a 22-year-old man who presented with an acute basilar artery occlusion.</span>72783283310.1001/jamaneurol.2015.0479http://archneur.jamanetwork.com/article.aspx?articleID=2383121Corticosteroid-Induced Paraplegiahttp://archneur.jamanetwork.com/article.aspx?articleID=2383122
Wed, 01 Jul 2015 00:00:00 GMTO’Keeffe DT, Mikhail MA, Lanzino G, et al. <span class="paragraphSection">This case report describes a man in his 60s who presented with groin numbness, incomplete bladder emptying, and leg weakness.</span>72783383410.1001/jamaneurol.2015.0757http://archneur.jamanetwork.com/article.aspx?articleID=2383122Factors Contributing to the Post–Lumbar Puncture Headachehttp://archneur.jamanetwork.com/article.aspx?articleID=2383120
Wed, 01 Jul 2015 00:00:00 GMTGolzari SJ, Mahmoodpoor A, Rikhtegar R. <span class="paragraphSection"><strong>To the Editor</strong> Factors associated with post–lumbar puncture headache occurrence have been thoroughly highlighted by Monserrate et al. The use of a smaller-tipped needle can decrease the incidence of headache (the protocol used in the study) provided that the number of punctures does not increase. Multiple punctures probably increase the incidence of headaches. If use of a smaller needle increases the number of punctures, the difference between small and large needles in producing headaches may be reduced. Therefore, the expertise of the person performing the puncture and the number of attempts are of importance; these seem to have been overlooked. Other important, yet missing, factors are pregnancy and needle bevel placement axis. The incidence of post–lumbar puncture headache increases with pregnancy, and it occurs less frequently when the needle bevel is placed parallel with the length of the neuraxis during insertion.</span>72783483510.1001/jamaneurol.2015.0694http://archneur.jamanetwork.com/article.aspx?articleID=2383120Factors Contributing to the Post–Lumbar Puncture Headachehttp://archneur.jamanetwork.com/article.aspx?articleID=2383123
Wed, 01 Jul 2015 00:00:00 GMTBateman RJ, Morris JC. <span class="paragraphSection"><strong>In Reply</strong> On behalf of the Dominantly Inherited Alzheimer Network, we thank Golzari and colleagues for their interest in our report and comments. We agree that the number of attempts made to obtain cerebrospinal fluid and the experience of the clinician with the specific needle type may be additional factors that could affect the incidence or severity of post–lumbar puncture headaches. We did not analyze this in our study because the number of needle insertions into the lumbar thecal space was not part of the study outcome. In our study, bevel orientation was not a significant factor because we specifically used a symmetric noncutting needle (Sprotte), which lacks a bevel. We also excluded participants who were pregnant from research lumbar puncture.</span>72783583510.1001/jamaneurol.2015.0691http://archneur.jamanetwork.com/article.aspx?articleID=2383123No Evidence of Disease Activity in Multiple Sclerosishttp://archneur.jamanetwork.com/article.aspx?articleID=2383119
Wed, 01 Jul 2015 00:00:00 GMTSloane JA, Mainero C, Kinkel R. <span class="paragraphSection"><strong>To the Editor</strong> No evidence of disease activity (NEDA) is becoming an important secondary outcome measure in multiple sclerosis (MS) clinical trials. In this context, the article by Rotstein and colleagues, demonstrating that NEDA at 2 years has potential prognostic significance, is timely. Interestingly, the authors found a dissociation between clinical and magnetic resonance imaging (MRI) disease activity, raising the question of whether the lack of disease progression truly reflects evidence of absence or absence of evidence.</span>72783583610.1001/jamaneurol.2015.0587http://archneur.jamanetwork.com/article.aspx?articleID=2383119JAMA Neurologyhttp://archneur.jamanetwork.com/article.aspx?articleID=2388779
Wed, 01 Jul 2015 00:00:00 GMT<span class="paragraphSection"><strong>Mission Statement:</strong> The mission of <span style="font-style:italic;">JAMA Neurology</span> is to publish scientific information primarily important for those physicians caring for people with neurologic disorders but also for those interested in the structure and function of the normal and diseased nervous system. These specific aims are (1) to make timely publication of original research of the nervous system, (2) to record observations of single patients or groups of patients that will provide new information and insights, (3) to report more basic research that is pertinent to the understanding of disease, (4) to introduce topics of practice, ethics, teaching, and history that are useful, (5) to provide a forum for discussion on topics that may be controversial in this field. This information will be published only after extensive peer review so that originality, clarity, and precision are ensured.</span>72773773710.1001/jamaneurol.2014.2857http://archneur.jamanetwork.com/article.aspx?articleID=2388779